Acadian Asset Management
CDTX

Acadian Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Acadian Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-47,079
Closed -$1.19M – 1745
2023
Q1 		$1.19M Sell
47,079
-15,751
-25% -$447K 0.01% 837
2022
Q4 		$948K Buy
62,830
+2,153
+4% +$25.7K ﹤0.01% 859
2022
Q3 		$760K Buy
60,677
+4,935
+9% +$68.1K ﹤0.01% 873
2022
Q2 		$545K Buy
55,742
+777
+1% +$9.6K ﹤0.01% 949
2022
Q1 		$914K Buy
54,965
+10,492
+24% +$178K ﹤0.01% 848
2021
Q4 		$1.13M Buy
44,473
+15,131
+52% +$471K ﹤0.01% 804
2021
Q3 		$1.31M Buy
29,342
+8,093
+38% +$307K 0.01% 775
2021
Q2 		$859K Buy
21,249
+6,766
+47% +$286K ﹤0.01% 974
2021
Q1 		$770K Sell
14,483
-2,199
-13% -$109K ﹤0.01% 1034
2020
Q4 		$668K Buy
16,682
+54
+0.3% +$2.69K ﹤0.01% 1130
2020
Q3 		$948K Buy
16,628
+3,332
+25% +$235K ﹤0.01% 928
2020
Q2 		$981K Buy
13,296
+3,985
+43% +$258K ﹤0.01% 971
2020
Q1 		$462K Buy
9,311
+5,610
+152% +$336K ﹤0.01% 977
2019
Q4 		$284K Buy
+3,701
New +$169K ﹤0.01% 1207
2019
Q3 		– Sell
-3,294
Closed -$111K – 1884
2019
Q2 		$111K Sell
3,294
-441
-12% -$18.3K ﹤0.01% 1355
2019
Q1 		$198K Sell
3,735
-331
-8% -$18.1K ﹤0.01% 1355
2018
Q4 		$191K Hold
4,066
– – ﹤0.01% 1126
2018
Q3 		$358K Sell
4,066
-260
-6% -$22.9K ﹤0.01% 959
2018
Q2 		$450K Buy
4,326
+2,301
+114% +$217K ﹤0.01% 915
2018
Q1 		$162K Buy
+2,025
New +$277K ﹤0.01% 1111

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Acadian Asset Management's CDTX Position: Q2 2023 in Review

Acadian Asset Management sold out of Cidara Therapeutics (CDTX) in Q2 2023, closing a stake of 47,079 shares — an estimated $1.19M sold.

Acadian Asset Management first reported a position in CDTX in Q1 2018 and held it in 20 quarters. The position peaked at $1.31M in Q3 2021. 52 funds tracked by Wall St. Rank hold CDTX as of Q2 2023.

  • Acadian Asset Management reported no remaining Cidara Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Acadian Asset Management sold 47,079 Cidara Therapeutics shares in Q2 2023, an estimated $1.19M.
  • Acadian Asset Management first reported a position in Cidara Therapeutics in Q1 2018 and held it in 20 quarters.
  • Acadian Asset Management's Cidara Therapeutics position peaked at $1.31M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2023.

Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.